Anterior gradient 2: A novel sensitive tumor marker for metastatic oral cancer

Cancer Letters

Volumn 339, Issue 2, 2013, Pages 270-278

  Chen, Yi Ting ^a   Ho, Chung Liang ^a,b   Chen, Po Ku ^a   Chen, Yuh Ling ^a   Chang, Chuan Fa ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anterior gradient 2; HSC 3; Metastasis; Oral squamous cell carcinoma

Indexed keywords

ANTERIOR GRADIENT 2; TUMOR MARKER; UNCLASSIFIED DRUG;

AGR2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CANCER CELL; CANCER GENETICS; CARCINOGENESIS; CELL ISOLATION; CELL TRANSFORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; DISEASE MARKER; GENE EXPRESSION PROFILING; HSC 3 5 CELL; HSC 3 CELL; HUMAN; HUMAN CELL; MESENCHYME; METASTASIS; MOUSE; MOUTH CANCER; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TRANSWELL INVASION ASSAY;

ANTERIOR GRADIENT 2; HSC-3; METASTASIS; ORAL SQUAMOUS CELL CARCINOMA;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883758354     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.025     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59(2009):225-249.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J Clin 2002, 55(2005):74-108.
4. Seiwert T.Y., Cohen E.E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005, 92:1341-1348.
5. Zini A., Czerninski R., Sgan-Cohen H.D. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med 2010, 39:299-305.
6. Peng C.H., Liao C.T., Peng S.C., Chen Y.J., Cheng A.J., Juang J.L., Tsai C.Y., Chen T.C., Chuang Y.J., Tang C.Y., Hsieh W.P., Yen T.C. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One 2011, 6:e23452.
7. Hsu D.S., Chang S.Y., Liu C.J., Tzeng C.H., Wu K.J., Kao J.Y., Yang M.H. Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. Cancer Sci 2010, 101:1029-1037.
8. Yamatoji M., Kasamatsu A., Kouzu Y., Koike H., Sakamoto Y., Ogawara K., Shiiba M., Tanzawa H., Uzawa K. Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer 2012, 130:2903-2911.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
10. Mathot L., Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci 2012, 103:626-631.
11. Terranova V.P., Hujanen E.S., Loeb D.M., Martin G.R., Thornburg L., Glushko V. Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 1986, 83:465-469.
12. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwan R.N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47:3239-3245.
13. Chu Y.W., Yang P.C., Yang S.C., Shyu Y.C., Hendrix M.J., Wu R., Wu C.W. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997, 17:353-360.
14. Brychtova V., Vojtesek B., Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett 2011, 304:1-7.
15. Kani K., Malihi P.D., Jiang Y., Wang H., Wang Y., Ruderman D.L., et al. Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate 2012.
16. Pohler E., Craig A.L., Cotton J., Lawrie L., Dillon J.F., Ross P., Kernohan N., Hupp T.R. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics: MCP 2004, 3:534-547.
17. Barraclough D.L., Platt-Higgins A., de Silva Rudland S., Barraclough R., Winstanley J., West C.R., Rudland P.S. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 2009, 175:1848-1857.
18. Zhang Y., Forootan S.S., Liu D., Barraclough R., Foster C.S., Rudland P.S., Ke Y. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007, 10:293-300.
19. Wu M.H., Hong H.C., Hong T.M., Chiang W.F., Jin Y.T., Chen Y.L. Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 2011, 17:1306-1316.
20. Matsui T., Ota T., Ueda Y., Tanino M., Odashima S. Isolation of a highly metastatic cell line to lymph node in human oral squamous cell carcinoma by orthotopic implantation in nude mice. Oral Oncol 1998, 34:253-256.
21. Chen J.Y., Tang Y.A., Huang S.M., Juan H.F., Wu L.W., Sun Y.C., Wang S.C., Wu K.W., Balraj G., Chang T.T., Li W.S., Cheng H.C., Wang Y.C. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 2011, 71:473-483.
22. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
23. Choudhury K.R., Yagle K.J., Swanson P.E., Krohn K.A., Rajendran J.G. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem 2010, 58:95-107.
24. Greene F.L. The American joint committee on cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002, 87:13-15.
25. Clayton T.M., Whitaker J.P., Sparkes R., Gill P. Analysis and interpretation of mixed forensic stains using DNA STR profiling. Forensic Sci Int 1998, 91:55-70.
26. Yoshino K., Iimura E., Saijo K., Iwase S., Fukami K., Ohno T., Obata Y., Nakamura Y. Essential role for gene profiling analysis in the authentication of human cell lines. Human Cell 2006, 19:43-48.
27. Momose F., Araida T., Negishi A., Ichijo H., Shioda S., Sasaki S. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 1989, 18:391-395.
28. Thompson E.W., Newgreen D.F., Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res 2005, 65:5991-5995. [discussion 5995].
29. Dumartin L., Whiteman H.J., Weeks M.E., Hariharan D., Dmitrovic B., Iacobuzio-Donahue C.A., Brentnall T.A., Bronner M.P., Feakins R.M., Timms J.F., Brennan C., Lemoine N.R., Crnogorac-Jurcevic T. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 2011, 71:7091-7102.
30. Wu Z.S., Wu Q., Ding X.D., Wang H.Q., Shen Y.X., Fang S.Y. Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance. Zhonghua Bing Li Xue Za Zhi 2008, 37:109-113.
31. Sweeny L., Liu Z., Bush B.D., Hartman Y., Zhou T., Rosenthal E.L. CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma. Exp Cell Res 2012, 318:1788-1798.
32. Higa A., Mulot A., Delom F., Bouchecareilh M., Nguyen D.T., Boismenu D., Wise M.J., Chevet E. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem 2011, 286:44855-44868.
33. Kani K., Malihi P.D., Jiang Y., Wang H., Wang Y., Ruderman D.L., Agus D.B., Mallick P., Gross M.E. Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate 2013, 73:306-315.
34. Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S. Growth of the malignant and nonmalignant human squamous cells in a protein-free defined medium. In Vitro Cell Dev Biol 1990, 26:849-856.
35. Ichwan S.J., Yamada S., Sumrejkanchanakij P., Ibrahim-Auerkari E., Eto K., Ikeda M.A. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 2006, 25:1216-1224.
36. Liao C.H., Yeh S.C., Huang Y.H., Chen R.N., Tsai M.M., Chen W.J., Chi H.C., Tai P.J., Liao C.J., Wu S.M., Cheng W.L., Pai L.M., Lin K.H. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocr Relat Cancer 2010, 17:99-111.
37. Qian X., Li C., Pang B., Xue M., Wang J., Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One 2012, 7:e37225.
38. Zhou J., Bi C., Cheong L.L., Mahara S., Liu S.C., Tay K.G., Koh T.L., Yu Q., Chng W.J. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011, 118:2830-2839.